- Investigational agent mirikizumab met its primary endpoint for patients with moderate to severe plaque psoriasis in a phase 2 randomized controlled trial (RCT).
Why this matters
- Mirikizumab, an anti-interleukin-23 monoclonal antibody, may represent a promising new therapy option.
- The primary objective was met (superiority to placebo for achieving ≥90% improvement in the Psoriasis Area and Severity Index [PASI90]) at week 16:
- 0% for placebo.
- 29.4% for mirikizumab 30 mg (P=.009 vs placebo).
- 58.8% for mirikizumab 100 mg (P<.001 vs placebo>
- 66.7% for mirikizumab 300 mg (P<.001 vs placebo>
- 205 patients with moderate to severe plaque psoriasis received placebo (N=52), mirikizumab 30 mg (N=51), mirikizumab 100 mg (N=51), or mirikizumab 300 mg (N=51) at weeks 0 and 8 and were evaluated at week 16.
- Funding: Eli Lilly and Company.
- Short study duration.